MoneyWorks4Me

Zydus Lifesciences informs about disclosure

03 Jan 2024 Evaluate

Zydus Lifesciences has informed that the Company has received an Assessment Order of FY 2017-18 on the issue pertaining to Input Tax Credit (‘ITC’). The details as required under regulation 30 of Listing Regulations read with SEBI Circular are enclosed. 

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1107.35 -9.65 (-0.86%)
19-Aug-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1889.00
Dr. Reddys Labs. 1174.50
Cipla 1417.75
Lupin 2213.05
Zydus Lifesciences 1107.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: